PNV Share Price Performance
AU$0
-1.49 (-100.00%)
Price AU$0
Fair ValueAU$1.00
Share Pricen/a
PolyNovo Limited Stock Price
- 3 Narratives written by author
- 3 Comments on narratives written by author
- 71 Fair Values set on narratives written by author
PNV Community Narratives
AN
Fair Value AU$1 9.5% undervalued intrinsic discount
Global Cost Pressures And Regulatory Risks Will Cripple Future Prospects
0users have liked this narrative
1users have commented on this narrative
7users have followed this narrative
AN
Fair Value AU$1.98 54.3% undervalued intrinsic discount
PNV: Improved Margins And Expansion Efforts Will Drive Future Upside
0users have liked this narrative
2users have commented on this narrative
39users have followed this narrative
AN
Fair Value AU$2.65 65.8% undervalued intrinsic discount
Aging Populations Are Set To Expand Global Advanced Tissue Care
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Global Cost Pressures And Regulatory Risks Will Cripple Future Prospects
Key Takeaways Mounting cost pressures, regulatory hurdles, and supply chain risks threaten profitability and growth despite ongoing expansion and innovation efforts. Growing competition and limited diversification beyond the core platform may erode market share and lead to volatile revenue and earnings.Read more
287
users have viewed this narrative0users have liked this narrative
1users have commented on this narrative
7users have followed this narrative
AN
AU$1
9.5% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
12.87% p.a.
Profit Margin
16.82%
Future PE
25.44x
Price in 2029
AU$1.24
PNV: Improved Margins And Expansion Efforts Will Drive Future Upside
Key Takeaways Expanding international presence and diversified product pipeline reduce risk and position PolyNovo for strong, stable long-term revenue growth. Investments in manufacturing and regulatory milestones are set to boost profitability, market penetration, and adoption in key healthcare markets.Read more
541
users have viewed this narrative0users have liked this narrative
2users have commented on this narrative
39users have followed this narrative
AN
AU$1.98
54.3% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
21.88% p.a.
Profit Margin
17.63%
Future PE
41.18x
Price in 2028
AU$2.45
Aging Populations Are Set To Expand Global Advanced Tissue Care
Key Takeaways Accelerating product adoption and international expansion are driving stronger-than-expected recurring revenues and a more diversified, resilient earnings profile. Operational leverage, premium pricing power, and new clinician-driven uses for products position the company for substantial outperformance and sustained high-margin growth.Read more
40
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
AU$2.65
65.8% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
26.2% p.a.
Profit Margin
20.75%
Future PE
41.81x
Price in 2028
AU$3.25
Trending Discussion
Recently Updated Narratives
AN
PNV: Updated Profitability Assumptions Will Support Balanced Future Return Potential
Fair Value: AU$1 9.5% undervalued intrinsic discount
7 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
PNV: Future P/E and Discount Rate Shift Will Support Upside Momentum
Fair Value: AU$1.98 54.3% undervalued intrinsic discount
39 followersusers have followed this narrative
2 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Populations Are Set To Expand Global Advanced Tissue Care
Fair Value: AU$2.65 65.8% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
PolyNovo Limited Key Details
About PNV
- Founded
- 1998
- Employees
- 301
- CEO
- WebsiteView website
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; Beta Cell implant, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
